Novel TRPA1 Antagonists are Multimodal Blockers of Human TRPA1 Channels: Drug Candidates for Treatment of Familial Episodic Pain Syndrome (FEPS)

@article{Herz2020NovelTA,
  title={Novel TRPA1 Antagonists are Multimodal Blockers of Human TRPA1 Channels: Drug Candidates for Treatment of Familial Episodic Pain Syndrome (FEPS)},
  author={Jeffrey M. Herz and Wannipat Buated and William J. Thomsen and Yasuo Mori},
  journal={The FASEB Journal},
  year={2020},
  volume={34}
}
The TRPA1 receptor‐channel is a therapeutic target for the discovery of novel pain drugs. In man, a single gain‐of‐function mutation in TRPA1, N855S, is known to be the cause of a familial episodic pain syndrome (FEPS). Multimodal activation by various stimuli is a fundamental feature of TRPA1 so that the precise manner in which TRPA1 and N855S‐TRPA1 is activated under pathophysiological conditions is not known, but is thought to be due to a combined effect of an array of inflammatory and…